Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$2.63 USD
+0.04 (1.54%)
Updated Aug 23, 2024 03:06 PM ET
After-Market: $2.64 +0.01 (0.38%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Minerva Neurosciences (NERV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.00 | $5.00 | $5.00 | 93.05% |
Price Target
Only one analyst offered a short-term price target of $5.00 for Minerva Neurosciences. This represents an increase of 93.05% from the last closing price of $2.59.
Analyst Price Targets (1 )
Broker Rating
Minerva Neurosciences currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on two recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | H.C. Wainwright & Co. | Douglas Tsao | Hold | Hold |
3/15/2024 | JMP Securities | Jason N Butler | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 2 |
Average Target Price | $5.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -1.01 |